Signing ceremony on the strategic collaboration between SINOPHARM CNPIC and BSBE
Published：2020-07-31
Source：[英文]九强生物
Jingzhen Liu, Chairman of Sinopharm, Jianwei Hu, Deputy General Manager of Sinopharm, Haibo Song, Chairman of CACLP Association, Zuojun Zou, Chairman of BSBE, Wang Xiaoya, Chairman of Maixin Bio, CICC Co-Board of director Junbao Shan attended the meeting.
Jindong Deng, deputy general manager and Board of director of Sinopharm presided over the signing ceremony.
The background of the cooperation is that BSBE will issue additional shares to Sinopharm, making Sinopharm as shareholder of BSBE. At the same time, this acquisition will help BSBE and Sinopharm make their entrance into the field of pathology and expand the vitro diagnostic market.
As Jingzhen Liu said, the corporation of Sinopharm and BSBE played an important role in the fighting the epidemic. At the same time, he pointed out that the cooperation for both firm is an important practice for Sinopharm to promote the reform of mixed ownership. It is vital to expand the business of vitro diagnostics and medical device manufacturing. The two enterprises cooperate in multiple areas such as R&D, sales and resources to gain competitiveness in overseas markets.
Zuojun Zou claims that Sinopharm has become the majority shareholder of BSBE. Sinopharm and BSBE will cooperate in multiple fields such as , channels, customers and governance. The cooperation will develop relevant industries and multi-channel business chain network.
Xiaoya Wang said that this acquisition will enhance business innovation under the current medical background and develop China's pathological diagnosis industry.
Junbao Shan claims that Sinopharm become majority stakeholder in BSBE, which develop China’s vitro diagnostic industry and achieve the strategy of “Healthy China”
Liang Hongjun, general manager of Sinopharm Investment and Zou Zuojun chairman of BSBE signed a strategic cooperation agreement on the spot, which will be a symbol of Sinopharm enter the field of in vitro diagnostics through cooperation with BSBE.
China National Pharmaceutical Investment Co., Ltd. is an investment and financing platform of Sinopharm. It is committed to being a professional investment and financing company in the pharmaceutical and health industry.
As one of the domestic providers of clinical in vitro diagnostic products and services, BESE currently has three major systems: "Biochemical Detection System", "Blood Coagulation Detection System" and "Blood Type Detection System". BSBE and MXB became shareholders of Sinopharm, which enhance cooperation between state-owned enterprises and private enterprises in the field of in vitro diagnostics.
In the future, Sinopharm will still concentrate to pharmaceutical and device manufacturing, pharmaceuticals, medical services and other related fields.